Core Insights - Erasca, Inc. is a clinical-stage precision oncology company focused on therapies for RAS/MAPK pathway-driven cancers [3] - The company will participate in several investor conferences in November 2025, including the Guggenheim 2nd Annual Healthcare Innovation Conference, Stifel 2025 Healthcare Conference, and Jefferies Global Healthcare Conference [1][2] Company Overview - Erasca aims to "erase cancer" by discovering, developing, and commercializing therapies specifically targeting RAS/MAPK pathway-driven cancers [3] - The company was co-founded by pioneers in precision oncology and RAS targeting, emphasizing the development of novel therapies and combination regimens [3] - Erasca's scientific advisory board includes leading experts in the RAS/MAPK pathway, enhancing the company's capabilities in achieving its mission [3] Upcoming Events - The company will engage in a fireside chat at the Guggenheim 2nd Annual Healthcare Innovation Conference on November 11, 2025, at 2:00 pm Eastern Time [2] - At the Stifel 2025 Healthcare Conference, Erasca will participate in a fireside chat on November 12, 2025, at 1:20 pm Eastern Time [2] - The Jefferies Global Healthcare Conference will feature Erasca in a fireside chat on November 19, 2025, at 10:30 am Greenwich Mean Time [2] - Live audio webcasts of these events will be available on Erasca's website, with archived replays accessible for 30 days post-event [2]